A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48).

Autor: Leng X; Department of Rheumatology and Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China., Leszczyński P; Department of Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland., Jeka S; Department of Rheumatology and Connective Tissue Diseases, University Hospital No 2, CM UMK, Bydgoszcz, Poland., Liu S; First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Liu H; Qilu Hospital of Shandong University, Jinan, China., Miakisz M; Twoja Przychodnia Centrum Medyczne, Nowa Sól, Poland., Gu J; The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Kilasonia L; Tbilisi Heart and Vascular Clinic Ltd, Tbilisi, Georgia., Stanislavchuk M; National Pirogov Memorial Medical University, Vinnytsia, Ukraine., Yang X; Bio-Thera Solutions Ltd, Guangzhou, China., Zhou Y; Bio-Thera Solutions Ltd, Guangzhou, China., Dong Q; Bio-Thera Solutions Ltd, Guangzhou, China., Mitroiu M; Biogen International GmbH, Baar, Switzerland., Addison J; Biogen Idec Ltd, Maidenhead, UK., Rezk MF; Biogen International GmbH, Baar, Switzerland., Zeng X; Department of Rheumatology and Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China. zengxfpumc@163.com.

Publikováno v: Arthritis research & therapy [Arthritis Res Ther] 2024 Sep 07; Vol. 26 (1), pp. 157. Date of Electronic Publication: 2024 Sep 07.

Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.

Autor: Mease P; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle., Helliwell P; University of Leeds, Leeds, UK., Silwinska-Stanczyk P; REUMATIKA-Centrum Reumatologii NZOZ, Warsaw, Poland., Miakisz M; Twoja Przychodnia Centrum Medyczne Nowa Sól, Nowa Sól, Poland., Ostor A; Monash University, Cabrini Hospital, and Emeritus Research, Melbourne, Victoria, Australia., Peeva E; Pfizer Inc, Cambridge, Massachusetts., Vincent MS; Pfizer Inc, Cambridge, Massachusetts., Sun Q; Pfizer Inc, Cambridge, Massachusetts., Sikirica V; Pfizer Inc, Collegeville, Pennsylvania., Winnette R; Pfizer Inc, New York, New York., Qiu R; Pfizer Inc, Cambridge, Massachusetts., Li G; Pfizer Inc, Collegeville, Pennsylvania., Feng G; Pfizer Inc, Cambridge, Massachusetts., Beebe JS; Pfizer Inc, Cambridge, Massachusetts., Martin DA; Pfizer Inc, Cambridge, Massachusetts.

Publikováno v: Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2023 Aug; Vol. 75 (8), pp. 1370-1380. Date of Electronic Publication: 2023 Jun 22.

Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition.

Autor: Dragotto, Martina¹ (AUTHOR) emanuele.trovato@ao-siena.toscana.it, D'Onghia, Martina¹ (AUTHOR) pietro.rubegni@unisi.it, Trovato, Emanuele¹ (AUTHOR), Tognetti, Linda¹ (AUTHOR), Rubegni, Pietro¹ (AUTHOR), Calabrese, Laura^1,2 (AUTHOR) laura.calabrese@unisi.it

Publikováno v: Journal of Clinical Medicine. Jun2024, Vol. 13 Issue 11, p3091. 15p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?

Autor: Avci AB; Department of Internal Medicine, Rheumatology, Medical Park Antalya Hospital, Antalya, Türkiye., Feist E; Department of Rheumatology, Helios Fachklinik Vogelsang-Gommern, Cooperation Partner of the Otto-von-Guericke University Magdeburg, Gommern, Germany., Burmester GR; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Medizinische Klinik für Rheumatologie und Klinische Immunologie, Charitéplatz 1, 10117, Berlin, Germany. gerd.burmester@charite.de.

Publikováno v: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2024 Jan; Vol. 38 (1), pp. 61-71. Date of Electronic Publication: 2023 Nov 21.